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The structural disruption of the mitochondrial inner membrane in hepatocytes lacking functional 
peroxisomes along with selective impairment of respiratory complexes and depletion of mitochondrial 
DNA was previously reported. In search for the molecular origin of these mitochondrial alterations, we 
here show that these are tissue selective as they do neither occur in peroxisome deficient brain nor in 
peroxisome deficient striated muscle. Given the hepatocyte selectivity, we investigated the potential 
involvement of metabolites that are primarily handled by hepatic peroxisomes. Levels of these 
metabolites were manipulated in L-Pex5 knockout mice and/or compared with levels in different mouse 
models with a peroxisomal β-oxidation deficiency. We show that neither the deficiency of 
docosahexaenoic acid nor the accumulation of branched chain fatty acids, dicarboxylic acids or C27 
bile acid intermediates are solely responsible for the mitochondrial anomalies. In conclusion, we 
demonstrate that peroxisomal inactivity differentially impacts mitochondria depending on the cell type 
but the cause of the mitochondrial destruction needs to be further explored. 
Highlights 
 Severe mitochondrial destruction in peroxisome deficient cells is hepatocyte selective 
 Isoprenoid-derived branched chain or dicarboxylic fatty acid overload alone does not induce 
the mitochondrial deficits 
 Shortage of docosahexaenoic acid and accumulation of bile acid intermediates do not correlate 
with pathology 
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In some early reports on patients with the most severe form of a peroxisome biogenesis disorder (PBD), 
Zellweger syndrome, mitochondrial aberrations were documented. In hepatocytes mitochondria with 
severely distorted cristae and altered appearance of the matrix were found [1-3]. However, the 
anomalies were variable in severity and in a few other patients no abnormalities were detected [4]. 
Milder mitochondrial ultrastructural changes were sporadically reported in brain and in muscle [1, 4-7]. 
With regard to functional deficits, data from patients are even scarcer, and disparate impairments of 
complexes I – IV were reported in liver, muscle and brain [1, 8].  
Mitochondrial anomalies were recapitulated in mice lacking PEX5 or PEX2, models for Zellweger 
syndrome [9, 10], confirming that primary peroxisomal defects cause secondary mitochondrial 
dysfunction in hepatocytes. In global Pex5-/- and Pex2-/- mice that die neonatally, the majority of hepatic 
mitochondria were severely affected with unusually shaped and sparse cristae [10, 11]. 
Spectrophotometric analyses revealed that activities of the respiratory complexes I and V were 
markedly reduced. In other tissues, such as heart, adrenals, smooth muscle cells and kidney, mild 
structural changes were noticed such as electron dense inclusions and enlargement of the 
intermembrane space but cristae were not affected to the same extent as in hepatocytes [11].  
More systematic studies on the links between loss of functional peroxisomes and mitochondrial integrity 
were performed in hepatocyte selective Pex5 knockout mice (L-Pex5-/-), that survive into adulthood [12]. 
The severe distortion of cristae was accompanied with multiple metabolic and functional changes. The 
activities of complex I (< 30% of control), and complex III and V (~ 60% of control) were reduced, 
whereas the activities of complex II and IV were unaltered. This resulted in impaired oxygen 
consumption and ATP production and compensatory metabolic changes driven by AMPK activation 
[13]. A remarkable finding was that complex V primarily occurred as sub-complexes that were not 
integrated in the membrane [14]. Furthermore, the expression of mitochondrial-encoded subunits was 
reduced concomitant with a decrease of the mitochondrial DNA/nuclear DNA ratio whereas nuclear 
encoded subunits were normal or even elevated [14].  
The causal relationship between peroxisome inactivity and the mitochondrial perturbations in 
hepatocytes remains to date unresolved. Here, we investigated the molecular links by first addressing 
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the tissue selectivity of the peroxisome-mitochondrial interaction. For this, the mitochondrial 
compartment was investigated in mice with selective inactivation of PEX5 in striated muscle and brain, 
tissues highly dependent on intact mitochondrial function [15].  
As we found that mitochondrial ultrastructure and complex I activity were preserved in peroxisome 
deficient brain, heart and skeletal muscle, we subsequently hypothesized that metabolites that are in 
particular deregulated in peroxisome deficient hepatocytes and less in other cell types could be the 
triggering factor. Several metabolic conversions are indeed preferentially handled by hepatic 
peroxisomes including the synthesis of docosahexaenoic acid (DHA) and the degradation of branched 
chain fatty acids (i.e. phytanic and pristanic acid), dicarboxylic acids (DCAs) and the shortening of the 
side chain of the C27-bile acid intermediates 3α,7α-dihydroxycholestanoic acid (DHCA) and 3α,7α,12α-
trihydroxycholestanoic acid (THCA) [16]. Notably, each of these metabolites was shown before to affect 
the respiratory chain. We investigated whether any of these metabolites could be the causative factors 
by measuring and manipulating their levels and relating these to mitochondrial function. Because the 
suspected metabolites are all dependent on peroxisomal β-oxidation, we performed parallel analyses 
in mice lacking enzymes of this pathway, either multifunctional protein 1 (MFP1 also called L-BP) [17] 
or multifunctional protein 2 (MFP2 also called D-BP/HSD17B4) [18].
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2. Materials and methods 
2.1. Mouse breeding and diets 
Global Pex5 knockout mice were previously described [11]. Tissue selective Pex5 knockout mice were 
obtained by crossing Pex5FL/FL mice [19] with various CRE expressing mouse lines. Liver-selective, L-
Pex5-/- mice [12] and neural cell-selective Nestin-Pex5-/- mice [20] were already reported. Pex5FL/FL were 
used as controls. Selective knockout of Pex5 in striated muscle was obtained by using Mck-Cre mice 
(Jackson Laboratories) [21].  Mfp2-/- mice were generated by breeding Mfp2+/- mice as described [18]. 
All mice were in Swiss/Webster background with the exception of the Mfp1 knockout mouse line that 
was in a mixed 129/Ola-C57Bl/6 background [17]. DHA (10 mg/mouse every two days) protected from 
oxidation through gelatin microencapsulation (MEG-3, Ocean Nutrition Inc.) was supplemented by 
gavage [22] to 4 weeks old L-Pex5-/- mice and control mice for a period of 4 weeks. Some other adult 
wild type mice were fed a phytol diet (0.5% in chow) for 2 weeks [23]. Mice were bred in the specific 
pathogen free animal housing facility of the KU Leuven, had ad libitum access to water and standard 
rodent food, and were kept on a 12-hour light and dark cycle. All animal experiments were performed 
in accordance with the "Guidelines for Care and Use of Experimental Animals" and fully approved by 
the Research Ethical committee of the KU Leuven (#190/2012). Liver tissue from Mfp1-/- and control 
mice fed a coconut diet was collected previously [24].  
2.2. Metabolic analyses 
Livers were collected, snap frozen and kept at -80°C until further use. The following metabolites were 
analyzed according to previously established procedures: bile acids by HPLC-negative ion electrospray 
tandem mass spectrometry [25], pristanic and phytanic acid by GC-MS [26, 27], DCAs by HPLC-MS 
[24] and plasmalogens by HPLC [20]. To quantify DHA in mitochondria, a crude mitochondrial fraction 
was isolated by differential centrifugation and further subjected to Percoll gradient centrifugation as 
described [14].  Lipids were transmethylated in 1 ml 3 M HCl by incubating for 4 hours at 90°C in the 
presence of 10 nmol internal standard; the methyl ester of 18-methylnonadecanoic acid. After cooling, 
the aqueous layer was extracted in 2 ml hexane, and this extract was taken to dryness under nitrogen 
flow and resuspended in 80 μl of hexane. One microliter of this solution was injected into a Hewlett 
Packard GC 5890 equipped with an Agilent J&W HP-FFAP, 25m, 0.20mm, 0.33µm GC Column and 
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eluting fatty acid methylesters were detected by flame ionization detection. Fatty acid concentrations 
were calculated using the known amount of internal standard and expressed as nmol per phosphorus 
content of the phospholipid fraction [28]. 
2.3. Measurement of complex I activity 
Complex I activity was determined as described previously [11] with minor modifications. Briefly, liver 
(from 2-weeks old and 4-8 weeks old mice), corpus callosum, spinal cord and brain cortex (from 12-
weeks old mice), and heart (from 15-weeks old mice) were homogenized in 19 volumes of 
homogenization buffer (210 mM mannitol, 70 mM sucrose, 5 mM HEPES, 1 mM EGTA, pH 7.2) using 
a borosilicate glass hand homogenizer on ice. Homogenates were subjected to a sonication step (4 
cycles of 10 seconds at amplitude 4, separated by a 20 second break) with a Soniprep 150 sonicator 
(MSE Scientific Instruments, Sussex, England). The decrease in NADH absorbance after oxidation by 
complex I in the presence of coenzyme Q was followed on a Perkin Elmer Lambda 25 UV/VIS 
spectrophotometer for 5 minutes. The reaction was carried out at 30°C. Results were expressed as 
U/mg of protein.    
2.4. Electron microscopy 
Mice were perfusion-fixed with 4% paraformaldehyde/0.05% glutaraldehyde (v/v) for electron 
microscopy [29]. Isolated brains were post-fixed by immersion in 4% glutaraldehyde in 0.1 M sodium 
cacodylate buffer (pH 7.4) at room temperature for 1 day and then at 4 °C for 2 days. Brain samples 
were processed for ultrastructural analysis as described [30]. 
2.5. Statistical analyses 
Statistical analysis was done using GraphPad Prism 5.01 software (CA, USA). Statistical significance 
was determined by performing either unpaired t-test; one-way ANOVA or two-way ANOVA based on 




3.1. Tissue selectivity of mitochondrial abnormalities in peroxisome deficiency  
In order to investigate the tissue selectivity of the severe anomalies at the inner mitochondrial 
membrane seen in adult PEX5 deficient hepatocytes, we checked mitochondrial structure and function 
in some other tissue selective Pex5 knockouts. As a readout, complex I activity, that is the most severely 
affected respiratory chain complex in hepatocytes, was monitored [12]. First, we checked whether, 
following albumin-Cre induced recombination of the Pex5 gene in hepatocytes, destruction of the inner 
mitochondrial membrane already occurred at an early time point. At the age of 2 weeks, the majority of 
mitochondria contained a paucity of cristae that were severely distorted. This was accompanied by 
reduced complex I activity in liver, similar to what was observed in adult liver (Fig. 1a,b). Subsequently, 
we inspected mitochondria in Nestin-Pex5-/- mice that lack functional peroxisomes in neural cells and 
that develop severe neurodegeneration with inflammatory demyelination and neuron loss [20, 31]. 
Remarkably, in contrast to the severe reduction of complex I activity in livers of L-Pex5-/- mice, this 
complex was normally active in corpus callosum (Fig. 1c), neocortex and spinal cord (Suppl Fig1a,b) of 
Nestin-Pex5-/- mice. Also by ultrastructural analysis, the mitochondrial anomalies seen in peroxisome 
deficient hepatocytes were not found in corpus callosum and cortex of Nestin-Pex5-/- mice despite 
severe deterioration of the tissue (Fig. 1d and suppl Fig. 1c).  We subsequently examined mitochondria 
in mice with Pex5 inactivation in striated muscle obtained by breeding Pex5FL/FL mice with Mck-Cre 
mice. Selective recombination of the Pex5 gene in the targeted tissue was confirmed by the absence 
of the full length transcript in heart and skeletal muscle but not in liver, kidney or spleen (Suppl Fig. 2a). 
Furthermore, the inactivation of peroxisomal function was illustrated by strongly reduced levels of 
plasmalogens in heart and skeletal muscle (Suppl Fig. 2b,c). Mck-Pex5 mice did not develop an overt 
phenotype under basal conditions and had a normal life span (to be published elsewhere).   
Spectrophotometric analysis revealed that in heart tissue of Mck-Pex5-/- mice complex I activity was 
unaffected (Fig. 1e). The preservation of mitochondria in muscle was further confirmed by electron 
microscopy showing normal morphology of mitochondria in heart (Fig. 1f). These results suggest that 
mitochondria are differentially affected according to the cell type in which peroxisome biogenesis is 
defective. This is further supported by our previous observation that complex I activity was normal in 
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mouse embryonic Pex5-/- fibroblasts [11]. This raised the question whether a reduction or accumulation 
of metabolites that are preferentially generated or degraded by hepatic peroxisomes, respectively, and 
less by other tissues are causative for the mitochondrial defects. We therefore explored whether 
deficiency of DHA, or accumulation of branched chain fatty acids, immature C27 bile acids or DCAs 
could underlie the mitochondrial defects.  
3.2. Restoration of depleted DHA does not improve mitochondrial anomalies 
The synthesis of the polyunsaturated fatty acid (PUFA) DHA depends on peroxisomal β-oxidation and 
occurs primarily in hepatocytes [32, 33]. We previously showed that DHA was markedly reduced in 
mitochondria isolated from L-Pex5-/- mice as well as in different phospholipid fractions of these 
mitochondria [14]. In order to restore the levels of this PUFA, we treated the mice with DHA orally (10 
mg/mouse every two days starting at the age of 4 weeks). After the treatment, DHA was replenished in 
total hepatic lipids (not shown) as well as in mitochondria of L-Pex5-/- mice, increasing slightly above 
the levels in mitochondria of control mice with or without DHA supplementation (Fig. 2a). However, the 
activity of complex I did not improve, remaining below 20% of control values (Fig. 2b). Taken together 
these results indicate that the deficiency of DHA is not the source of the mitochondrial abnormalities. 
3.3. No evidence for the involvement of branched chain fatty acids in mitochondrial 
aberrations in L-Pex5-/- mice 
The catabolism of the branched chain fatty acid phytanic acid requires the consecutive action of 
peroxisomal α- and β-oxidation generating pristanic acid as an intermediate. Phytanic acid is derived 
from the dietary precursor phytol. Mice fed normal chow are only exposed to low levels of phytol and 
branched chain fatty acids. Still, we have previously reported increased concentrations of both phytanic 
and pristanic acids in the livers of L-Pex5-/- mice amounting to 0.16 and 0.69 pmol/nmol phospholipids, 
respectively, which was about 20 fold higher than in wild type mice [12]. According to several in vitro 
experiments these branched chain fatty acids are toxic for mitochondria [34]. In order to investigate 
whether the complex I impairments in L-Pex5 knockout mice may be caused by accumulating branched 
chain fatty acids, we treated wild type mice with the precursor phytol (0.5% in chow for 2 weeks). This 
induced an increase of phytanic acid levels in liver to 8 (male) and 61 (female) pmol/nmol and of 
pristanic acid to 26 (male) and 48 (female) pmol/nmol phospholipid [23]. Remarkably, although these 
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levels were several fold higher than in liver of L-Pex5 knockout mice on normal chow, complex I activity 
was not impaired in the liver of these treated mice (Fig. 3).  
3.4. DCAs do not accumulate in PEX5 deficient liver 
DCAs are formed in the endoplasmic reticulum (ER) through ω-hydroxylation of fatty acids by members 
of the Cyp4a family of cytochrome P450 enzymes that are enriched in liver and kidney [35]. These 
enzymes are positively regulated by PPARα [36] and we previously demonstrated that they are 
markedly upregulated in the livers of L-Pex5-/- mice [12, 37]. The breakdown of long and medium chain 
DCAs occurs through peroxisomal β-oxidation. Hence, the increased formation and hampered 
degradation of DCA in hepatocytes lacking functional peroxisomes is expected to lead to the 
accumulation of DCAs which could potentially be toxic for mitochondria [38-40]. We therefore 
determined the concentrations of DCAs of different carbon lengths in the livers of L-Pex5-/- and littermate 
control mice. Surprisingly, we did not find increased levels of short or medium length DCAs in the livers 
of L-Pex5-/- mice, and long chain DCAs were not detectable (Fig. 4a). To further investigate the 
possibility that DCAs cause mitochondrial anomalies, we measured complex I activity in a mouse model 
in which it was proven that DCAs accumulate. Indeed, Mfp1-/- mice fed with coconut diet, a rich source 
of C12 fatty acids, were recently reported to accumulate C4 – C14 DCAs [24]. Analyses of complex I 
activity in liver specimens of the mice previously used for DCA quantification, revealed normal function  
when compared to littermate controls (Fig. 4b). Together, these observations do not support the 
possibility that an accumulation of DCA is responsible for causing the mitochondrial abnormalities in 
the livers of L-Pex5-/- mice. 
3.5. Accumulating immature C27 bile acids do not underlie mitochondrial 
abnormalities in PEX5 deficient liver 
Hepatic peroxisomes are pivotal for the conversion of cholesterol into mature bile salts, as both the side 
chain shortening and the conjugation steps occur in this organelle, and bile acid synthesis primarily 
takes place in the liver. As expected, in liver of L-Pex5-/- mice immature C27 bile acids accumulated 
and mature C24 bile acids were severely reduced, resulting in a marked increase of the C27/C24 bile 
acid ratio (sum of conjugated and unconjugated species) when compared to control littermates (Fig. 5a 
and Table 1). Whereas the bulk of C24 bile acids were taurine conjugated in both genotypes, the 
majority of C27 bile acids in L-Pex5-/- liver occurred in the unconjugated form (Table 1). It was thereby 
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striking that levels of DHCA were 3-fold higher than the more hydrophilic THCA (Table 1) that is formed 
by 12-hydroxylation of 4-cholesten-7α-ol-3-one during the synthesis of bile acids. Importantly, 
Ferdinandusse et al previously showed that unconjugated DHCA was the most toxic of a panel of bile 
acids, impairing cell viability and ATP production in isolated mitochondria [41]. 
To examine whether the altered bile acid content could cause the mitochondrial anomalies, we 
compared the bile acid profiles and mitochondrial integrity in livers of L-Pex5-/- and Mfp2-/- mice, another 
mouse model with impaired bile acid synthesis. MFP2 is necessary for the side chain shortening of 
immature C27 bile acids as it catalyzes two steps in the peroxisomal β-oxidation. The inactivity of MFP2 
caused the predicted increase of the C27/C24 ratio (sum of conjugated and unconjugated species), 
which was even higher as in L-Pex5-/- livers (Fig. 5a). However, this altered bile acid profile in Mfp2-/- 
livers, even more distorted as in L-Pex5-/- livers, was not accompanied by overt mitochondrial anomalies 
as complex I activity was unaltered in Mfp2-/- livers (Fig. 5b), which was in line with previous observations 
of conserved mitochondrial ultrastructure [42]. 
Closer inspection of the accumulating C27 bile acids, revealed that besides a similar accumulation of 
unconjugated C27 bile acids in both models, conjugated C27 bile acids were markedly more elevated 
in Mfp2-/-   as compared to L-Pex5-/- liver (Table 1). Notably, in contrast to Pex5 deficient livers, the C27 
bile acid species in Mfp2-/- livers comprised more THCA than DHCA (Table 1) and both were primarily 
present in their 24-enoic form, consistent with intact peroxisomal acyl-CoA oxidase 2 (ACOX2) activity 
[16].  
It thus appeared that the level of the presumably most toxic bile acid, unconjugated DHCA, was 5-fold 
higher in L-Pex5-/- as compared to Mfp2-/- livers, which correlated with mitochondrial failure (Table 1, 
Figure 5d). To investigate whether the high DHCA levels are the cause of the mitochondrial disruption 
in L-Pex5-/- mice we performed a comparative study in prenatal Pex5-/- and Mfp2-/-  mice. According to 
recent information, levels of bile acids and their synthesizing enzymes are low prenatally and are 
strongly induced on the day of birth in mice [43]. So, we turned to constitutive Pex5 knockout mice, in 
which we previously observed mitochondrial anomalies already one day before birth [11] and checked 
whether DHCA and THCA levels were already affected at this age. As a comparison we also measured 
the levels of these bile acid intermediates at the same age in Mfp2-/- liver in which no mitochondrial 
abnormalities were detected. Importantly, we found that in E18.5 livers unconjugated THCA levels were 
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already grossly elevated in both Mfp2-/-  and Pex5-/- livers reaching levels similar to those in adult mice 
(Fig. 5c and Table 1). In contrast, DHCA levels were much lower in E18.5 compared to adult livers and 
again comparable in both genotypes (Fig. 5d). Thus, the accumulation of DHCA (L-Pex5-/-adult >>> Mfp2-
/-
adult >> Pex5-/-prenatal  > Mfp2-/-prenatal) and THCA (Pex5-/-prenatal ~ Mfp2-/-adult > L-Pex5-/-adult ~ Mfp2-/-prenatal)  
do not correlate with the structural and functional mitochondrial anomalies that were observed in both 
prenatal and adult Pex5 knockouts but not in Mfp2-deficient liver.  Therefore, the abnormal bile acid 




Peroxisomes and mitochondria have been shown to have close interplay with respect to various 
biochemical and cell biological aspects; most important being the co-operation during the fatty acid 
oxidation process and detoxification of oxygen radicals. In our previous work we have shown that in 
hepatocytes mitochondrial integrity depends on intact peroxisomal function. In the present study we 
investigated whether the mitochondrial abnormalities are caused by an accumulation or shortage of 
peroxisomal metabolites. We showed that the impaired mitochondrial function is not due to reduced 
levels of DHA or to accumulation of the branched chain fatty acids phytanic and pristanic acid, 
dicarboxylic fatty acids, or the peroxisomal C27 bile acid intermediates.  
The suspicion that peroxisomal metabolites could be causative factors was raised by the finding that 
the mitochondrial impairment due to peroxisomal dysfunction is cell type selective. An important 
observation in this respect has been that the structure and function of the mitochondrial inner membrane 
was preserved in the central nervous system and in striated muscle that are selectively depleted from 
intact peroxisomes. This differs from the mild and sporadic changes in mitochondrial structure in muscle 
tissue of global Pex5 knockouts [11] and we therefore assume that the latter were induced by non-cell 
autonomous mechanisms. In addition to brain and muscle, we previously showed that activities of the 
electron transport chain complexes were normal in Pex5 deficient fibroblasts [11]. Together, our data 
do not prove absolute cell type selectivity, but they suggest that a metabolic alteration that mainly takes 
place in hepatocytes is responsible for the mitochondrial damage. It can however not be excluded that 
the differential mitochondrial impairment is merely related to the larger volume of the peroxisomal 
compartment in hepatocytes. It is indeed well known that peroxisomes in hepatocytes are more 
numerous and larger in size compared to other tissues where they are often named microperoxisomes. 
It should be noted that mitochondrial dysfunction was reported in other situations of a primary 
peroxisomal defect e.g. in B12 oligodendrocytes and U87 astrocytes from which the ATP binding 
cassette subfamily D member 1 (ABCD1-) was deleted [44]; in fibroblasts from X-ALD patients and in 
spinal cords of Abcd1-/- mice [45], and in muscle biopsies from patients with a mutation in PEX12 or 
PEX16 [6]. However, the mitochondrial distress in these cell types was much less pronounced than in 
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L-Pex5-/- liver with regard to respiratory complex activities and structure of the inner mitochondrial 
membrane.  
For some metabolic processes, peroxisomes in hepatocytes seem to be less essential compared to 
other tissues. We previously found normal levels of plasmalogens and very long chain fatty acids in 
liver of L-Pex5-/- mice [12] which is in contrast with their respective depletion and accumulation in brain 
of Nestin-Pex5-/- mice [20]. This allowed to disregard these peroxisomal metabolites as the source of 
the mitochondrial anomalies in hepatocytes.  
The synthesis of DHA, which primarily takes place in liver [46], requires one cycle of peroxisomal β-
oxidation, explaining the shortage of this PUFA in livers without functional peroxisomes. We previously 
showed that DHA levels were reduced in all phospholipid classes in isolated mitochondria from Pex5 
knockout livers, including in cardiolipin [14]. Alterations in the PUFA composition of mitochondrial 
phospholipids has diverse consequences on mitochondrial function such as impairments of 
mitochondrial permeability transition pore causing mitochondrial depolarization, uncoupling, swelling, 
defects of oxidative phosphorylation, loss of ATP production and cytochrome c release leading to 
apoptosis or necrosis [47-49]. We could however exclude that the reduced levels of DHA are the cause 
of the mitochondrial anomalies in PEX5 deficient hepatocytes as replenishing the liver with exogenous 
DHA did not improve mitochondrial function. An additional argument pleading against a role of DHA is 
that the pathological peroxisomal-mitochondrial connection is cell autonomous [12]. A minority of 
hepatocytes that escape loss of PEX5 and maintain import competent peroxisomes also harbor intact 
mitochondria, sharply delineated from neighboring cells with destroyed peroxisomal and mitochondrial 
compartments. In contrast, DHA produced by intact hepatocytes is expected to distribute in the liver 
and to other tissues of the organism. 
The branched chain fatty acids phytanic and pristanic acid were shown to impair mitochondria in various 
ways including the membrane potential, NAD(P)H levels, activity of respiratory complexes, production 
of reactive oxygen species (ROS), opening of the mitochondrial transition pore, size and shape [50-52]. 
These fatty acids derive from phytol liberated from chlorophyll in ruminants and are taken up by humans 
when ingesting dairy products and meat. Failure of peroxisomal α- and/or β-oxidation in patients with 
peroxisomal disorders causes markedly increased levels of branched chain fatty acids resulting in 
pathologies primarily in the peripheral nervous system and in cerebellum [16]. Pathological 
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concentrations of phytanic acid were shown to depolarize mitochondria in different experimental 
conditions supposedly mediated by inhibition of complex I [50, 51] or by a protonophoric mechanism of 
action [52]. However, we could rule out that the profound impairment of complex I activity in L-Pex5 
knockout liver was due to the mildly increased levels of phytanic and pristanic acid. Indeed, even 10-
50 fold higher hepatic levels of these branched chain fatty acids, induced by feeding wild type mice a 
phytol enriched diet, did not affect complex I activity, although it induced morphological hepatic changes 
as described [23, 53]. 
Omega-oxidation of fatty acids in the ER, accounting for 5-10% of total fatty acid metabolism under 
normal conditions [38], converts (very) long chain fatty acids to DCAs and is catalyzed by cytochrome 
P450 enzymes. Formed DCAs depend strictly on peroxisomal β-oxidation for their catabolism to shorter 
chain lengths and after further degradation in mitochondria are finally excreted in urine [54-56]. 
Peroxisomal acyl-CoA oxidase (ACOX1) is one of the central enzymes involved in the β-oxidation of 
DCAs. Acox1-/- mice have been shown to develop steatohepatitis which was attributed to the 
accumulation of DCAs [40, 57]. These di-anionic fatty acids can damage mitochondria and inhibit 
mitochondrial β-oxidation by dissipation of the mitochondrial proton gradient and uncoupling oxidative 
phosphorylation along with increased ROS generation during the oxidation process itself [38-40]. Liver 
mitochondria treated with Reye's Syndrome serum, which has as high as 54% of DCAs in total serum 
fatty acids, significantly uncoupled mitochondrial respiration and distorted mitochondrial ultrastructure 
[58]. Contrary to our expectations, we did not find increased levels of DCAs in L-Pex5 knockout livers, 
not even when mice were fed a DCA generating coconut diet (data not shown). This is surprising given 
that such diet strongly raised DCA levels in Mfp1 knockout mouse liver. Considering that in the latter 
mouse livers, despite extensive pathology that led to premature death [24], no changes at the level of 
complex I activity occur, we can exclude that DCA are at the origin of mitochondrial damage in L-Pex5-
/- mice.  
Bile acids are primarily synthesized in liver from cholesterol and peroxisomes are essential both for the 
side chain shortening by β-oxidation and the conjugation steps [59, 60]. Inactivity of the β-oxidation 
leads to accumulation of C27 bile acid intermediates DHCA and THCA. In cholestatic liver disease 
characterized by accumulation of mature bile acids, mitochondrial abnormalities have been reported in 
the liver. For this reason the toxicity of bile acids has been extensively studied using either intact hepatic 
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cells or isolated liver mitochondria of rodent or human origin. Bile acids have been shown to inhibit 
respiratory complexes, respiratory uncoupling, increased superoxide/ROS production, mitochondrial 
transition pore opening, apoptotic and necrotic cell death which was more prominent when hydrophobic 
bile acids were used [61-66]. The toxicity of the C27 bile acid intermediates in their conjugated or non-
conjugated form was investigated by Ferdinandusse and colleagues  using the rat hepatoma cell line 
McA-RH7777 [41]. The unconjugated C27 bile acids, in particular DHCA, were the most potent in 
inducing cell death and in inhibiting oxidative phosphorylation thereby increasing ROS production. 
Although unconjugated DHCA and THCA accumulate in L-Pex5-/- liver, our data do not provide evidence 
that these destroy the inner mitochondrial membrane. Indeed, the levels of these bile acid species in 
liver of Mfp2-/- and L-Pex5-/- mice at different ages did not correlate with crippled mitochondria in Pex5 
deficiency from the neonatal period throughout adulthood, and preserved mitochondria in Mfp2 mutants 
at all ages.  
In summary, we show that mitochondria in hepatocytes are more vulnerable to cell autonomous 
functional peroxisomal deficits than mitochondria in other cell types. As several peroxisome related 
metabolite abnormalities that are most prominent in peroxisome-deficient hepatocytes could not be 
linked to the mitochondrial defects, the molecular link between defective peroxisomes and inner 
mitochondrial membrane disruption remains mysterious. However, it needs to be emphasized that in 
this study overall levels of these metabolites were measured and further refinements are required to 
exclude changes in intermediates, e.g. carnitine-esters and CoA-esters. On the other hand, it cannot 
be excluded that a combination of deregulated metabolites causes the mitochondrial deficits. 
Alternatively, it needs to be envisaged that other than metabolic factors are involved.  
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Figure 1: Mitochondrial abnormalities are tissue selective 
(a,c,e) Complex I activities in tissues of conditional Pex5 knockout compared to the respective control 
(Ct) mice.  Complex I activity is strongly reduced in adult (left panel) and P14 (right panel) livers of L-
Pex5-/- (a) but not in corpus callosum of Nestin-Pex5-/- (c) neither in heart of Mck-Pex5-/- mice (e). All 
values are expressed as mean ± SEM (n = 4-5). P<0.01: **; p<0.001: *** L-Pex5-/- versus control mice. 
Electron micrographs of hepatocytes of P14 control and L-Pex5-/- mice (b) show severely altered 
mitochondrial ultrastructure while those of corpus callosum of Nestin-Pex5-/- mice (d) as well as heart 
of Mck-Pex5-/- mice (f) show normal mitochondrial ultrastructure.   
Figure 2: DHA levels do not correlate with mitochondrial complex I activity 
(a) DHA is depleted in the mitochondria of L-Pex5-/- liver and restored above levels in control mice after 
oral DHA supplementation. (b) The reduced complex I activity in the livers of L-Pex5-/- mice is not altered 
after replenishing DHA levels. All values are expressed as mean ± SEM (n= 3). p<0.01:**, p<0.001: *** 
versus control untreated; p<0.001: ### L-Pex5-/- mice treated with DHA versus L-Pex5-/- mice. 
Plipid=phospholipid 
Figure 3: Branched chain fatty acid accumulation does not impair complex I activity  
(a) Complex I activity in the livers of wild type (WT) mice fed with phytol diet was not different from wild 
type mice on regular chow, despite significant accumulation of phytanic and pristanic acid. All values 
are expressed as mean ± SEM (n = 3). 
Figure 4: DCA levels do not correlate with mitochondrial alterations 
(a)  Relative levels of C3 to C14 DCAs in the livers of L-Pex5-/- mice on normal chow (left panel). The 
sum of all DCAs measured in control liver was set to 100% and the value for each DCA in control and 
L-Pex5-/- mice was calculated as % of this sum, taking into account tissue weight and the internal 
standard methyl malonic acid. Total DCA level in L-Pex5-/- liver was 80% of total DCA level in control 
liver (right panel). (b) Complex I activity in the livers of Mfp1-/- mice was not different from controls, both 
fed with coconut diet. All values are expressed as mean ± SEM (n=4). p<0.001: *** L-Pex5-/- versus 
control mice. 
 Figure 5: Accumulating immature C27 bile acids are not associated with complex I impairment 
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(a) The ratio of immature C27 to mature C24 bile acids is significantly increased in the livers of adult L-
Pex5-/- and even more in Mfp2-/- mice in comparison to littermate controls. (b) Complex I activity in the 
livers of Mfp2-/- mice is not impaired in comparison to littermate controls. (c-d) Absolute values of 
unconjugated THCA and unconjugated DHCA, respectively in the livers of adult L-Pex5-/-, adult Mfp2-/-
, E18.5 Pex5-/- and E18.5 Mfp2-/- mice. Unconjugated DHCA is the sum of unconjugated forms of DHCA 
and Δ24-DHCA while unconjugated THCA is the sum of unconjugated forms of THCA, Δ24-THCA, OH-
THCA and Δ24-OH-THCA. Observed profiles of unconjugated forms of THCA and DHCA in these mice 
do not correlate with the mitochondrial anomalies. All values are expressed as mean ± SEM (n=4), L-
Pex5-/-, Pex5-/- and Mfp2-/- mice versus respective control mice p<0.05: * ; p<0.01:*; p<0.001: ***. 
 
Supplementary Figure 1: Mitochondrial abnormalities are tissue selective 
Complex I activities in brain cortex (a) and spinal cord (b) of Nestin-Pex5-/- mice along with their 
respective littermate controls (Ct). No significant differences were found in both tissues when compared 
to their respective controls. (c) Electron micrographs of brain cortex of control and Nestin-Pex5-/- mice 
showing normal mitochondrial ultra-structure.   
Supplementary Figure 2: Inactivation of the Pex5 gene in Mck-Pex5 knockout mice 
(a)  Northern blot analysis shows a truncated Pex5 transcript in heart and skeletal muscle of Mck-Pex5-
/- mice as compared to controls (left panel), but not in liver, kidney and spleen (right panel) indicating 
selective recombination of the Pex5 gene in the targeted tissue. Reduced levels of plasmalogens in 
heart (b) and skeletal muscle (c) of Mck-Pex5-/- mice demonstrate effective inactivation of peroxisomal 
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Table 1: Conjugated and unconjugated C24 and C27 bile acids in liver of Ct, L-Pex5-/-, Pex5-/- and Mfp2-/- mice. 












Ct 319 ± 75 281 ± 62 36 ± 13 0.35 ± 0.30 1.66 ± 0.41 0.53 ± 0.19 1.12 ± 0.61 
L-Pex5-/- 189 ± 34 142 ± 44 8.1 ± 4.0 7.0 ± 0.5* 41 ± 2*** 31.92 ± 0.77*** 10.97 ± 4.06** 
Ct 489 ± 32 457 ± 36 31 ± 4 0.21 ± 0.10 0.7 ± 0.2 0.04 ± 0.04 0.33 ± 0.39 
Mfp2-/- 192 ± 25*** 72 ± 15*** 5.1 ± 2.0** 87 ± 11*** 36 ± 8** 7.14 ± 1.95* 27.64 ± 8.59** 
Ct 123 ± 15 121 ± 15 0.54 ± 0.08 0.27 ± 0.05 0.30 ± 0.05 0.15 ± 0.04 0.15 ± 0.01 
Pex5-/- 39 ± 3*** 8.9 ± 1.6*** 1.16 ± 0.07*** 0.63 ± 0.11* 28.06 ± 2.13*** 1.86 ± 0.16*** 26.19 ± 2.12*** 
Ct 91 ± 14 90 ± 14 0.37 ± 0.07 0.49 ± 0.11 0.31 ± 0.02 0.09 ± 0.01 0.22 ± 0.03 
Mfp2-/- 38 ± 3** 14.0 ± 2.1** 3.46 ± 0.31*** 6.39 ± 0.67*** 13.83 ± 0.7*** 0.66 ± 0.1** 13.17 ± 0.76*** 
All values are in pmol/mg liver. Values are expressed as mean ± SEM. Unconjugated DHCA is the sum of unconjugated DHCA and Δ24-DHCA 
whereas unconjugated THCA is the sum of unconjugated THCA, Δ24-THCA, OH-THCA and Δ24-OH-THCA. L-Pex5-/-, Pex5-/- or Mfp2-/- mice 
versus respective control mice; p<0.05: *; p<0.01: **; p<0.001: ***. 
 
 
